Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study

Advanced differentiated thyroid cancer; Epidemiological study; Survival prognostic factors

Detalles Bibliográficos
Autores: Vallejo Casas, Juan Antonio, Sambo, Marcel, López López, Carlos, Duran-Poveda, Manuel, Rodriguez-Villanueva García, Julio, Santos, Rita Joana, Zafon Llopis, Carles
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/8282
Acceso en línea:https://hdl.handle.net/11351/8282
http://hdl.handle.net/11351/8282
Access Level:acceso abierto
Palabra clave:Tiroide - Càncer - Tractament
Tiroide - Càncer - Prognosi
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms
Other subheadings::Other subheadings::/therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroides
Otros calificadores::Otros calificadores::/terapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
id ES_04e91190baeed49e4c73bfa5d25104f1
oai_identifier_str oai:recercat.cat:11351/8282
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
title Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
spellingShingle Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
Vallejo Casas, Juan Antonio
Tiroide - Càncer - Tractament
Tiroide - Càncer - Prognosi
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms
Other subheadings::Other subheadings::/therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroides
Otros calificadores::Otros calificadores::/terapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
title_short Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
title_full Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
title_fullStr Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
title_full_unstemmed Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
title_sort Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
dc.creator.none.fl_str_mv Vallejo Casas, Juan Antonio
Sambo, Marcel
López López, Carlos
Duran-Poveda, Manuel
Rodriguez-Villanueva García, Julio
Santos, Rita Joana
Zafon Llopis, Carles
author Vallejo Casas, Juan Antonio
author_facet Vallejo Casas, Juan Antonio
Sambo, Marcel
López López, Carlos
Duran-Poveda, Manuel
Rodriguez-Villanueva García, Julio
Santos, Rita Joana
Zafon Llopis, Carles
author_role author
author2 Sambo, Marcel
López López, Carlos
Duran-Poveda, Manuel
Rodriguez-Villanueva García, Julio
Santos, Rita Joana
Zafon Llopis, Carles
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Vallejo Casas JA] Department of Nuclear Medicine (UGC), Maimónides Institute of Biomedical Research of Córdoba (IMIBIC), Reina Sofía University Hospital, University of Córdoba, Córdoba, Spain. [Sambo M] Department of Endocrinology, Gregorio Marañón University Hospital, Madrid, Spain. [López López C] Department of Medical Oncology, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain. [Durán-Poveda M] Department of General and Digestive Surgery, Rey Juan Carlos University Hospital, Madrid, Spain. [Rodríguez-Villanueva García J] Oncology Business Group – EISAI Farmacéutica SA, Madrid, Spain. [Santos RJ] Department of Endocrinology, Francisco Gentil Portuguese Institute of Oncology of Lisbon, Lisbon, Portugal. [Zafón C] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Tiroide - Càncer - Tractament
Tiroide - Càncer - Prognosi
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms
Other subheadings::Other subheadings::/therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroides
Otros calificadores::Otros calificadores::/terapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
topic Tiroide - Càncer - Tractament
Tiroide - Càncer - Prognosi
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms
Other subheadings::Other subheadings::/therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroides
Otros calificadores::Otros calificadores::/terapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
description Advanced differentiated thyroid cancer; Epidemiological study; Survival prognostic factors
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/8282
http://hdl.handle.net/11351/8282
url https://hdl.handle.net/11351/8282
http://hdl.handle.net/11351/8282
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv European Thyroid Journal;11(5)
http://dx.doi.org/10.1530/ETJ-21-0111
dc.rights.none.fl_str_mv Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Bioscientifica
publisher.none.fl_str_mv Bioscientifica
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402822509854720
spelling Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT studyVallejo Casas, Juan AntonioSambo, MarcelLópez López, CarlosDuran-Poveda, ManuelRodriguez-Villanueva García, JulioSantos, Rita JoanaZafon Llopis, CarlesTiroide - Càncer - TractamentTiroide - Càncer - PrognosiDISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid NeoplasmsOther subheadings::Other subheadings::/therapyANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::PrognosisENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroidesOtros calificadores::Otros calificadores::/terapiaTÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronósticoAdvanced differentiated thyroid cancer; Epidemiological study; Survival prognostic factorsCáncer de tiroides diferenciado avanzado; Estudio epidemiológico; Factores pronósticos de supervivenciaCàncer de tiroide diferenciat avançat; Estudi epidemiològic; Factors pronòstics de supervivènciaBackground Up to 30% of differentiated thyroid cancer (DTC) will develop advanced-stage disease (aDTC) with reduced overall survival (OS). Objective The aim of this study is to characterize initial diagnosis of aDTC, its therapeutic management, and prognosis in Spain and Portugal. Methods A multicentre, longitudinal, retrospective study of adult patients diagnosed with aDTC in the Iberian Peninsula was conducted between January 2007 and December 2012. Analyses of baseline characteristics and results of initial treatments, relapse- or progression-free survival ((RP)FS) from first DTC diagnosis, OS, and prognostic factors impacting the evolution of advanced disease were evaluated. Results Two hundred and thirteen patients (median age: 63 years; 57% female) were eligible from 23 hospitals. Advanced disease presented at first diagnosis (de novo aDTC) included 54% of patients, while 46% had relapsed from early disease (recurrent/progressive eDTC). At initial stage, most patients received surgery (98%) and/or radioiodine (RAI) (89%), with no differences seen between median OS (95% CI) (10.4 (7.3–15.3) years) and median disease-specific-survival (95% CI) (11.1 (8.7–16.2) years; log-rank test P = 0.4737). Age at diagnosis being <55 years was associated with a lower risk of death (Wald chi-square (Wc-s) P < 0.0001), while a poor response to RAI to a higher risk of death ((Wc-s) P < 0.05). In the eDTC cohort, median (RP)FS (95% CI) was of 1.7 (1.0–2.0) years after RAI, with R0/R1 surgeries being the only common significant favourable factor for longer (RP)FS and time to aDTC ((Wc-s) P < 0.05). Conclusion Identification of early treatment-dependent prognostic factors for an unfavourable course of advanced disease is possible. An intensified therapeutic attitude may reverse this trend and should be considered in poor-performing patients. Prospective studies are required to confirm these findings.ERUDIT study was sponsored and funded by Eisai Farmacéutica S.A. (Madrid, Spain).BioscientificaInstitut Català de la Salut[Vallejo Casas JA] Department of Nuclear Medicine (UGC), Maimónides Institute of Biomedical Research of Córdoba (IMIBIC), Reina Sofía University Hospital, University of Córdoba, Córdoba, Spain. [Sambo M] Department of Endocrinology, Gregorio Marañón University Hospital, Madrid, Spain. [López López C] Department of Medical Oncology, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain. [Durán-Poveda M] Department of General and Digestive Surgery, Rey Juan Carlos University Hospital, Madrid, Spain. [Rodríguez-Villanueva García J] Oncology Business Group – EISAI Farmacéutica SA, Madrid, Spain. [Santos RJ] Department of Endocrinology, Francisco Gentil Portuguese Institute of Oncology of Lisbon, Lisbon, Portugal. [Zafón C] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, SpainVall d'Hebron Barcelona Hospital Campus202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/8282http://hdl.handle.net/11351/8282Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésEuropean Thyroid Journal;11(5)http://dx.doi.org/10.1530/ETJ-21-0111Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/82822026-05-29T05:05:01Z
score 15,812429

Similares en LA Referencia